Johnson & Johnson Reports registry Data for Dupilumab in Hemophilia A

Johnson & Johnson today announced registry results for dupilumab in patients with hemophilia A. The study demonstrated that dupilumab demonstrates durable remissions compared to standard of care or placebo. These results provide important insights into the treatment of hemophilia A and support the continued development of dupilumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.